7 completed, 4 terminated, 4 withdrawn, 3 active not recruiting. 20 Phase 2, 3 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 20 | Completed 7, Terminated 4, Withdrawn 4, Active not recruiting 3, Recruiting 2 |
| Phase 3 | 3 | Completed 2, Recruiting 1 |
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
Follow Relapsing Multiple Sclerosis: new trials by email Literature Review of Relapsing Multiple Sclerosis trials Research Report on Relapsing Multiple Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis Ublituximab, Placebo, Fingolimod - Relapsing Multiple Sclerosis | Phase 2 / Phase 3 | Recruiting | TG Therapeutics, Inc. | 240 | 2026-07-01 | 2026-10-29 |
| A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS) Fenebrutinib - Relapsing Multiple Sclerosis | Phase 2 | Recruiting | Hoffmann-La Roche | 12 | 2025-10-06 | 2026-11-09 |
| An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis rapcabtagene autoleucel (YTB323) - Relapsing Multiple Sclerosis | Phase 1 / Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 28 | 2025-02-24 | 2026-09-02 |
| A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone) Obexelimab, Placebo - Relapsing Multiple Sclerosis | Phase 2 | Active not recruiting | Zenas BioPharma (USA), LLC | 93 | 2024-08-26 | 2025-11-17 |
| A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis Placebo, Pirtobrutinib - Relapsing Multiple Sclerosis, Multiple Sclerosis | Phase 2 | Withdrawn | Loxo Oncology, Inc. | 2024-05-01 | 2024-03-27 | |
| A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis Mitoxantrone Hydrochloride Liposome Injection - Relapsing Multiple Sclerosis | Phase 2 | Withdrawn | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 2022-08-01 | 2022-12-15 | |
| A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS) Fenebrutinib, Placebo - Relapsing Multiple Sclerosis | Phase 2 | Active not recruiting | Hoffmann-La Roche | 109 | 2022-03-01 | 2026-09-25 |
| Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS) Placebo, BIIB061, Interferon-beta1 - Relapsing Multiple Sclerosis | Phase 2 | Withdrawn | Biogen | 2021-06-30 | 2023-06-01 | |
| A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis CNM-Au8 - Relapsing Multiple Sclerosis | Phase 2 / Phase 3 | Completed | Clene Nanomedicine | 55 | 2020-10-22 | 2023-12-08 |
| Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis Tolebrutinib - Relapsing Multiple Sclerosis | Phase 2 | Completed | Sanofi | 125 | 2019-09-23 | 2025-10-23 |
| Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis SAR442168, Placebo, Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging (MRI) - Relapsing Multiple Sclerosis | Phase 2 | Completed | Sanofi | 130 | 2019-03-29 | 2025-09-17 |
| Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab Ofatumumab, Matching placebo of ofatumumab - Relapsing Multiple Sclerosis | Phase 2 | Completed | Novartis Pharmaceuticals | 64 | 2018-03-15 | 2022-04-29 |
| Fecal Microbial Transplantation in Relapsing Multiple Sclerosis Patients Fecal microbiota - Autoimmune Diseases, Relapsing Multiple Sclerosis | Phase 2 | Terminated | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 14 | 2017-08-24 | 2019-12-02 |
| Natalizumab Subcutaneous Immunogenicity and Safety Study natalizumab - Relapsing Multiple Sclerosis | Phase 2 | Terminated | Biogen | 2 | 2014-12-01 | 2024-06-03 |
| Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients Ozanimod, Placebo - Relapsing Multiple Sclerosis | Phase 2 / Phase 3 | Completed | Celgene | 258 | 2012-09-18 | 2021-02-11 |
| A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability Laquinimod 0.6, Laquinimod 1.2, Glatiramer Acetate or interferon-beta+ Placebo - Relapsing Multiple Sclerosis | Phase 2 | Withdrawn | Teva Branded Pharmaceutical Products R&D, Inc. | 2012-03-01 | 2013-08-27 | |
| Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study Trichuris suis ova - Relapsing Multiple Sclerosis | Phase 2 | Completed | Copenhagen University Hospital, Rigshospitalet | 10 | 2010-05-01 | 2011-11-10 |
| Atacicept in Multiple Sclerosis Extension Study, Phase II Atacicept 25 mg, Atacicept 75 mg, Atacicept 150 mg - Relapsing Multiple Sclerosis | Phase 2 | Terminated | EMD Serono | 74 | 2009-03-01 | 2017-03-20 |
| CDP323 Biomarker Study CDP323, Placebo - Relapsing Multiple Sclerosis | Phase 1 / Phase 2 | Completed | UCB Pharma | 71 | 2008-07-01 | 2011-09-12 |
| A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS) Atacicept, Placebo matched to atacicept - Relapsing Multiple Sclerosis | Phase 2 | Terminated | EMD Serono | 255 | 2008-04-01 | 2016-05-24 |
Multiple Sclerosis (6) · Autoimmune Diseases (1) · Demyelinating Diseases (1) · Optic Nerve Diseases (1) · Optic Neuritis (1)
Autoimmune Diseases of the Nervous System (6) · Demyelinating Autoimmune Diseases, CNS (6) · Immune System Diseases (6) · Nervous System Diseases (6) · Autoimmune Diseases (5) · Demyelinating Diseases (5) · Cranial Nerve Diseases (1) · Eye Diseases (1)
Glatiramer Acetate (2) · TACI receptor-IgG Fc fragment fusion protein (2) · fenebrutinib (2) · CDP323 (1) · Coat Protein Complex I (1) · Fecal Microbiota Transplantation (1) · Fingolimod Hydrochloride (1) · Interferon beta-1a (1) · Interferon beta-1b (1) · Interferon-beta (1) · Natalizumab (1) · ofatumumab (1) · ozanimod (1) · peginterferon beta-1a (1) · pirtobrutinib (1)
Biogen (2) · EMD Serono (2) · Hoffmann-La Roche (2) · Novartis Pharmaceuticals (2) · Sanofi (2) · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (1) · Celgene (1) · Clene Nanomedicine (1) · Copenhagen University Hospital, Rigshospitalet (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · Loxo Oncology, Inc. (1) · TG Therapeutics, Inc. (1) · Teva Branded Pharmaceutical Products R&D, Inc. (1) · UCB Pharma (1) · Zenas BioPharma (USA), LLC (1)
United States (9) · Spain (8) · Czechia (6) · Russia (6) · Ukraine (6) · Belgium (5) · Canada (5) · France (5) · Australia (4) · Netherlands (4) · Poland (4) · United Kingdom (4) · Germany (3) · Italy (3) · Slovakia (3)
Daniel Mikol, MD, PhD (1) · Marcelo Kremenchutzky, MD, FRCP (1) · Ralf Gold, MD (1)
PMID 24613349, PMID 23472197, PMID 25698173, PMID 26879276, PMID 30043658, PMID 34418400, PMID 40683275
2018 (2), 2014 (1), 2019 (1), 2025 (1)